SEC EDGAROct 26$HTFL

Rogers Campbell sold $1.3M of HTFL

Rogers Campbell (Chief Medical Officer) sold 23,933 shares of Heartflow, Inc. (HTFL) at $55.01 ($1.32M total) on 2026-10-22 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Rogers Campbell

Published Oct 26, 2026, 10:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 26, 2026, 10:02 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HTFL

Bearish

high confidence

Mentioned

$HTFL

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HTFLBearishLow

Why it matters

The sale reduces insider ownership and may be interpreted as a lack of confidence, but the pre‑arranged nature tempers the signal.

Market read

A modest insider sell by a senior executive, disclosed via Form 4, offers a low‑to‑moderate trading signal for HTFL.

What to watch

The 10b5‑1 plan indicates the sale was pre‑scheduled, reducing the informational value of the transaction.

Relevance 5/10Novelty 6/10Timing: after‑hours filing today

Background

Form 4 disclosures provide the first public record of insider transactions, which traders monitor for potential signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HTFLBearishHigh confidence

Context

Chief Medical Officer Rogers Campbell sold 23,933 shares for $1.3M via a 10b5‑1 plan, reducing his stake to 73,453 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell

Evidence & confidence

Form 4 filings are primary disclosures; a $1.3M sale by a CMO is material for a mid‑cap biotech and can trigger short‑term selling.

Market effects

Sector

May raise concerns about insider sentiment in the medical device/diagnostics sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing under a pre‑arranged plan, not a negative signal.

Key entities

Company
Heartflow, Inc.
Medical imaging company listed on NASDAQ under HTFL.
Person
Rogers Campbell
Chief Medical Officer of Heartflow.

Read at source ← All news

Med

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

finance.yahoo.comNov 14

Med

Canaccord Genuity maintains HeartFlow at Buy, raises price target to $69 from $56

Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.

tradingview.comNov 13

High

Stifel maintains HeartFlow at Buy, raises price target to $70 from $45

Stifel upgraded its price target for HeartFlow to $70 from $45, a 55.6% increase, implying 16.8% upside from the Nov 12 close of $59.92. The firm maintained its Buy rating on the company.

tradingview.comNov 13

$HTFLMed

Stifel raises HeartFlow stock price target to $70 on strong growth

Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.

investing.comNov 13

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

finance.yahoo.comNov 13

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.